APOGEE THERAPEUTICS INC (APGE)
Sector: Health Care
2026 Annual Meeting Analysis
APOGEE THERAPEUTICS INC · Meeting: June 9, 2026
Directors FOR
2
Directors AGAINST
1
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of Three Class III Director Nominees
Against Analysis
Mr. McKenna is the sitting CEO of Mirador Therapeutics and simultaneously serves on the boards of Apogee, Spyre Therapeutics, and NewAmsterdam Pharma — that is three outside public company board seats while serving as a CEO, which exceeds the policy limit of two outside board seats for a sitting CEO, raising concerns that his primary fiduciary obligations to Mirador shareholders may be stretched too thin.
For Analysis
Ms. Fox is an independent director with strong financial expertise, qualifies as an audit committee financial expert, served on all required committees with adequate attendance, and Apogee's 3-year stock return of 303.3% outperforms the XBI — SPDR S&P Biotech ETF's 3-year return of 67.5% by approximately 236 percentage points, far exceeding the 65-percentage-point threshold that would trigger a concern, so no TSR-based flag applies.
Mr. Jones is an independent director with relevant commercial and pharmaceutical industry experience, met the 75% attendance requirement, and Apogee's exceptional stock performance relative to the XBI — SPDR S&P Biotech ETF means no TSR underperformance trigger applies to any director on this slate.
Of the three Class III nominees, Jennifer Fox and William (BJ) Jones, Jr. receive FOR votes — both are independent, well-qualified, and the company's strong stock performance (3-year return of 303.3% vs. XBI's 67.5%) means no TSR trigger fires for any director. Mark McKenna receives an AGAINST vote solely because he is the sitting CEO of Mirador Therapeutics and holds board seats at three outside public companies (APGE, SYRE, NAMS), exceeding the policy's two-seat limit for a sitting CEO.
Say on Pay
✓ FORCEO
Michael Henderson, M.D.
Total Comp
$1,291,500
Prior Support
N/A
The CEO's total reported compensation for 2025 was $1,291,500 — consisting of $700,000 in base salary and a $591,500 cash bonus — with no equity grant reported in the Summary Compensation Table for 2025 (the equity grant cycle shifted to January of the following year), which is modest for a CEO of a $6.4 billion biotech company and well within reasonable benchmarks. The pay structure is heavily performance-linked: the company reports that 95% of CEO pay is 'at risk,' annual bonuses are tied to pre-set clinical and operational milestones (paid out at 130% of target after meaningful pipeline achievements), and the equity program uses stock options that only have value if the stock price rises. The company also has a clawback policy, no excise tax gross-ups, no single-trigger change-in-control payments, and stock performance has been exceptional (303.3% over three years vs. 67.5% for XBI — SPDR S&P Biotech ETF), confirming that incentive pay is well-aligned with shareholder outcomes.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
3 yrs
Audit Fees
$1,190,000
Non-Audit Fees
$0
Ernst & Young has served as Apogee's auditor since 2023 (approximately three years), well below the 25-year tenure threshold that would raise independence concerns; non-audit fees were zero in 2025, meaning the non-audit fee ratio is 0%, far below the 50% threshold; and EY is a Big 4 firm appropriate for a $6.4 billion market-cap company.
Overall Assessment
The 2026 Apogee Therapeutics annual meeting presents three standard proposals: the board slate receives split votes with FOR on Fox and Jones but AGAINST on McKenna due to his overboarding as a sitting CEO, the auditor ratification is straightforward with a clean fee profile and young tenure, and the Say on Pay vote is supportable given modest reported CEO pay, a performance-linked pay structure, and outstanding stock returns relative to the XBI — SPDR S&P Biotech ETF benchmark. There are no stockholder proposals on the ballot.